Physician profile
Wei K Kao
NPI 1629295571
$13,897.05
in general payments reported to CMS, 2019-2025
64 companies · $2,016 in 2025
The $2,016 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,456 · 2020: $1,606 · 2021: $1,710 · 2022: $1,836 · 2023: $2,400 · 2024: $1,873 · 2025: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,262 · Education: $26.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,262.09 |
| Education | $26.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,237.17 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Novo Nordisk INC | $1,365.05 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $985.13 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $971.89 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Acadia Pharmaceuticals INC | $732.57 | 2020-2024 | Nuplazid |
| Pfizer INC. | $700.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $542.55 | 2019-2025 | |
| Esperion Therapeutics, INC. | $452.11 | 2020-2025 | Nexletol |
| Abbvie INC. | $422.36 | 2021-2025 | |
| Amgen INC. | $396.64 | 2019-2025 | Evenity, Prolia, Repatha |
| Regeneron Healthcare Solutions, INC. | $382.95 | 2019-2023 | Evkeeza |
| Glaxosmithkline, LLC. | $373.85 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $321.47 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $281.18 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.72 | 2019-2024 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Kao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.